Abnormal maternal behaviour in mice previously immunized against progesterone

1992 ◽  
Vol 134 (2) ◽  
pp. 257-267 ◽  
Author(s):  
M.-W. Wang ◽  
R. B. Heap ◽  
M. J. Taussig

ABSTRACT Anti-progesterone immunization leads to reversible infertility in mice; this can be achieved by passive immunization with a monoclonal antibody to progesterone (DB3), or by active immunization with either a progesterone–protein (bovine serum albumin; BSA) conjugate or anti-idiotype directed against DB3. Recovery of fertility in treated females varied from 39·5 to 75·5 median days after passive or active (progesterone–BSA) immunization respectively. Litter size after the first pregnancy also differed from 8·6 ±0·8 to 5·0 ±0·6 (mean ± s.e.m.) per mother after passive or active immunization respectively. When litter size was standardized to a maximum of four pups per litter, aberrant maternal responses were observed in the first 5 days after delivery in 40–70% of the nursing mothers. These responses took the forms of cannibalism and failure to retrieve or to nurse pups and resulted in a high incidence of pup rejection (up to 40%), compared with no rejection in control mothers. When mothers were allowed to keep entire litters, an even higher incidence of pup rejection occurred (51% compared with 8% in controls). There was an apparent relation between the degree of negative maternal behaviour and the progesterone antibody concentration in the circulation during the infertile period. Whereas aberrant behaviour occurred mainly within the first 5 days of lactation, it was significantly reduced thereafter. Aberrant behaviour of the mother towards pups may be a consequence of the presence of residual progesterone antibodies in the circulation which affects the process of progesterone withdrawal at parturition that is essential for the establishment of normal maternal responses to the neonate. Journal of Endocrinology (1992) 134, 257–267

2022 ◽  
Author(s):  
Heinz-Josef Schmitt ◽  
Khrystyna Hrynkevych

The respiratory syncytial virus (RSV) is an RNA virus that causes annual ARI outbreaks during winter with mild URTI in the general population, but with severe LRTI particularly among young children (bronchiolitis), patients with underlying diseases and people >65 years of age. RSV does not induce a long-lasting protective immunity and repeated infections throughout life are the norm. Basically, all children have been infected by 2 years of age and of those hospitalized, >50% are <3 months and 75% are <6 months of age. The overall CFR is 1/500. For adults ≥65 years, RSV hospitalization rates are 90–250/105. There is no specific therapy, general preventive measures include general hygiene and isolation/separation of patients. A monoclonal anti-F-protein antibody is available for passive immunization of selected high-risk children. It requires monthly injections, comes at a high cost and has limited efficacy (50% against RSV hospitalization). Active immunization failed in the past, probably as the post-fusion conformation of the F-protein was used. Long-acting monoclonal antibodies (for infants) as well as stabilized pre-fusion F-protein vaccines (for immunization of pregnant women, children, older adults) produced on various platforms are in late stages of clinical development.


PEDIATRICS ◽  
1991 ◽  
Vol 88 (2) ◽  
pp. 379-383
Author(s):  
MARK D. WIDOME

There was a little man, and he had a little gun, And his bullets were made of lead, lead, lead; He went to the brook, and he saw a little duck, And he shot it through the head, head, head. —Mother Goose Four decades ago, Harry Dietrich,1 a member of the American Academy of Pediatrics' newly established Accident Prevention Committee, described a developmentally based approach to the prevention of childhood injury. Dietrich stressed the great need for protection ("passive immunization") for the young child and for safety education ("active immunization") as the child matures. It was also in the early 1950s that George Wheatley, the first chairman of the Accident Prevention Committee, popularized the "three E's"2—education, enforcement, and engineering—as a framework for developing and categorizing strategies to prevent injuries.


PEDIATRICS ◽  
1959 ◽  
Vol 23 (2) ◽  
pp. 430-430
Author(s):  
C. ARDEN MILLER

This book begins: "Biological products used in infectious diseases may be divided into three groups, namely: 1) Sera of various types for prophylaxis and treatment by passive immunization; 2) Prophylactics, such as toxins, toxoids, and vaccines (both bacterial and viral), for active immunization; 3) Diagnostic products, such as diluted toxins and tuberculins, used by the clinician to detect the presence or absence of immunity and also of allergy. Most of these materials come within the scope of this book.


1988 ◽  
Vol 255 (6) ◽  
pp. G723-G730 ◽  
Author(s):  
J. S. Redfern ◽  
E. Lee ◽  
M. Feldman

Active immunization of rabbits with a 6-ketoprostaglandin F1 alpha-thyroglobulin conjugate induced gastrointestinal ulceration, whereas active immunization of rabbits with 13,14-dihydro-15-keto prostaglandin E2-thyroglobulin conjugate or with thyroglobulin alone did not result in ulceration. Passive immunization of a separate group of rabbits with 6-ketoprostaglandin F1 alpha-hyperimmune plasma, obtained from actively 6-ketoprostaglandin F1 alpha-immunized donor rabbits that had ulcers, induced gastric ulceration within 9 days, whereas passive immunization of rabbits with control plasma, obtained from donor rabbits actively immunized with thyroglobulin alone, did not induce ulceration. Ulcerogenic donor plasma containing antibody to 6-ketoprostaglandin F1 alpha neutralized the inhibitory actions of prostacyclin on adenosine diphosphate-induced platelet aggregation, indicating that this antibody cross-reacted with prostacyclin. In contrast, plasma containing antibodies to 13,14-dihydro-15-ketoprostaglandin E2 cross-reacted only slightly with prostaglandin E2. Thus antibodies to inactive metabolites of prostaglandins induce ulceration only if these antibodies cross-react with an endogenous, "cytoprotective" prostaglandin.


2017 ◽  
Vol 247 ◽  
pp. 100-107 ◽  
Author(s):  
Stefanie Wiedmer ◽  
Alaa Aldin Alnassan ◽  
Beate Volke ◽  
Ahmed Thabet ◽  
Arwid Daugschies ◽  
...  

1993 ◽  
Vol 33 (6) ◽  
pp. 721 ◽  
Author(s):  
G Alexander ◽  
LR Bradley ◽  
D Stevens

Behavioural factors associated with lamb mortality were examined in regard to the relative effects of age and parity in single-bearing Merino ewes. Primiparas tended to have longer labour and higher lamb mortality than multiparous ewes. Maternal behaviour in primiparas was characterised by more desertions, a smaller proportion that stood and started to groom their lambs immediately after birth, and a larger proportion with non-cooperative behaviour during the initial sucking attempts of the lamb. These traits, and a high incidence of malpresentations, were particularly marked in 5-year-old primiparas deliberately denied access to rams in previous seasons. There was no evidence of improved maternal behavioural attributes associated with increasing age of ewe that were independent of previous experience in giving birth and rearing lambs.


2001 ◽  
Vol 56 (3) ◽  
pp. 79-90 ◽  
Author(s):  
Lucia Ferro Bricks

Respiratory syncytial virus is the most important cause of viral lower respiratory illness in infants and children worldwide. By the age of 2 years, nearly every child has become infected with respiratory syncytial virus and re-infections are common throughout life. Most infections are mild and can be managed at home, but this virus causes serious diseases in preterm children, especially those with bronchopulmonary dysplasia. Respiratory syncytial virus has also been recognized as an important pathogen in people with immunossupressive and other underlying medical problems and institutionalizated elderly, causing thousands of hospitalizations and deaths every year. The burden of these infections makes the development of vaccines for respiratory syncytial virus highly desirable, but the insuccess of a respiratory syncytial virus formalin-inactivated vaccine hampered the progress in this field. To date, there is no vaccine available for preventing respiratory syncytial virus infections, however, in the last years, there has been much progress in the understanding of immunology and immunopathologic mechanisms of respiratory syncytial virus diseases, which has allowed the development of new strategies for passive and active prophylaxis. In this article, the author presents a review about novel approaches to the prevention of respiratory syncytial virus infections, such as: passive immunization with human polyclonal intravenous immune globulin and humanized monoclonal antibodies (both already licensed for use in premature infants and children with bronchopulmonary dysplasia), and many different vaccines that are potential candidates for active immunization against respiratory syncytial virus.


1948 ◽  
Vol 46 (1) ◽  
pp. 34-41 ◽  
Author(s):  
A. W. Downie ◽  
A. T. Glenny ◽  
H. J. Parish ◽  
E. T. C. Spooner ◽  
R. L. Vollum ◽  
...  

Three sets of experiments were carried out on undergraduate medical students at Oxford, Cambridge and Liverpool during the years 1941–4 in order to supplement the information obtained previously (Downie et al. 1941) on the comparative antitoxin response of those given active immunization alone (Group A) and those given combined active and passive immunization (Group A+P). A summary of each of the experiments has already been given in the text, so that it is unnecessary here to do more than recapitulate briefly the main results.1. The first experiment showed that in Group A the antitoxin response was not appreciably greater in students receiving doses of 0·3 and 0·3–0·5 ml. of A.P.T. at 4 weeks’ interval than in those receiving doses of only 0·1 and 0·3 ml. In Group A + P no difference was noticed in the antitoxin content of the serum 6–8 weeks after the second injection of A.P.T., but 10–12 weeks after the second injection there was a difference in favour of the students receiving the larger doses of A.P.T., though it was below the conventional level of statistical significance.2. The second experiment showed that when the doses of A.P.T. were spaced by 2 instead of by 4 weeks the antitoxin response was much less in both the A and the A + P groups, though the difference was less in the latter group, particularly when the measurements were made 10–12 weeks after the second inoculation of A.P.T.3. The third experiment showed that a dose of 5000 units of diphtheria antiserum given at the time of the first injection of A.P.T. inhibited antitoxin production to a greater extent than a dose of 400–500 units, though the difference was much less when the measurements were made at 12 weeks after the second inoculation than at 4 weeks.A compilation of the results obtained during 1940–2 in groups of students receiving active and those receiving active plus passive immunization shows that the antitoxin production in the first group (Group A) was much higher than in the second group (Group A + P) 6–8 weeks after the second injection of A.P.T., but that 10–12 weeks after the second inoculation the difference, though still significant, was considerably less. The final Schick-test results at 10–12 weeks gave a Schick-conversion rate of 98.0% in Group A and of 90.9% in Group A + P.A review of the results obtained during the years 1939–44 on about 450 students at Oxford, Sheffield and Liverpool leads to the conclusion that the effect of giving diphtheria antiserum at the time of the first injection of A.P.T. is to cause a delay and some degree of inhibition in the antitoxin response of the subject. The larger the amount of antiserum given, the greater is this effect. With a dose of 500 units, though the delay in antitoxin formation is very obvious 4 weeks after the second injection of A.P.T., the final degree of immunity attained, as judged by the antitoxin concentration of the blood serum and by the Schick-conversion rate, is not greatly inferior to that resulting from active immunization alone; and even with a dose of 5000 units, the Schick-conversion rate reaches 81 % 12 weeks after the second injection of A.P.T. It is clear, therefore, that the antiserum, even when given in a dose as large as 5000 units, does not neutralize more than a small part of the antigenic activity of the first dose of A.P.T. Its main effect is apparently to diminish the rate of sensitization of the tissues, so that when a second dose of A.P.T. is given 4 weeks later, the rise in the antitoxin content of the blood serum is considerably delayed. Our experiments suggest that by increasing the size of the first dose of A.P.T., some of this delay may be avoided.The partial neutralization of the first dose of A.P.T. will result in a decrease in the total antigenic stimulus and a delay in the time at which ït comes into operation. It is suggested that, provided the tissues have not been previously sensitized to diphtheria toxin, the result may be that the two doses will act virtually as a single dose. Such an explanation, however, must remain unproven till further observations have been made (see p. 35).The practical value of combined active and passive immunization, especially when joined with temporary segregation of healthy carriers, in combating outbreaks of diphtheria in schools and other institutions for children has been clearly shown by Fulton, Taylor, Wells & Wilson (1941). Our present experiments lead us to suggest that, when applying the method in practice, it would be wise to give an initial dose of 0·5 ml. of A.P.T., together with 500 units of diphtheria antiserum injected at a different site, followed 6 weeks later by a second dose of 0.5 ml. A.P.T. It is probable that children treated in this way will develop approximately the same ultimate degree of immunity as those actively immunized with doses of 0·3 and 0·5 ml. of A.P.T. at 4 weeks’ interval.We should like to express our thanks to Prof. A. D. Gardner and Prof. H. R. Dean for permitting observations to be made on the students in the pathology classes at Oxford and Cambridge; and to the students themselves at Oxford, Cambridge and Liverpool, for their ready co-operation in the inquiry.


2005 ◽  
Vol 79 (7) ◽  
pp. 4033-4042 ◽  
Author(s):  
Daphne Nikles ◽  
Patricia Bach ◽  
Klaus Boller ◽  
Christoph A. Merten ◽  
Fabio Montrasio ◽  
...  

ABSTRACT Passive immunization with antibodies directed against the cellular form of the prion protein (PrPC) can protect against prion disease. However, active immunization with recombinant prion protein has so far failed to induce antibodies directed against native PrPC expressed on the cell surface. To develop an antiprion vaccine, a retroviral display system presenting either the full-length mouse PrP (PrP209) or the C-terminal 111 amino acids (PrP111) fused to the transmembrane domain of the platelet-derived growth factor receptor was established. Western blot analysis and immunogold electron microscopy of the retroviral display particles revealed successful incorporation of the fusion proteins into the particle membrane. Interestingly, retroviral particles displaying PrP111 (PrPD111 retroparticles) showed higher incorporation efficiencies than those displaying PrP209. Already 7 days after intravenous injection of PrPD111 retroparticles, PrPC-deficient mice (Prnp o/o) showed high immunoglobulin M (IgM) and IgG titers specifically binding the native PrPC molecule as expressed on the surface of T cells isolated from PrPC-overexpressing transgenic mice. More importantly, heterozygous Prnp +/o mice and also wild-type mice showed PrPC-specific IgM and IgG antibodies upon vaccination with PrPD111 retroparticles, albeit at considerably lower levels. Bacterially expressed recombinant PrP, in contrast, was unable to evoke IgG antibodies recognizing native PrPC in wild-type mice. Thus, our data show that PrP or parts thereof can be functionally displayed on retroviral particles and that immunization with PrP retroparticles may serve as a novel promising strategy for vaccination against transmissible spongiform encephalitis.


2007 ◽  
Vol 57 (2) ◽  
pp. 81-88
Author(s):  
Bulent Ekiz ◽  
Omur Kocak ◽  
Mustafa Ozcan ◽  
Alper Yilmaz

Sign in / Sign up

Export Citation Format

Share Document